These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28358994)

  • 1. Questioning the Effectiveness of Baricitinib for Pulmonary Manifestations of Rheumatoid Arthritis.
    Chertoff J; Ataya A
    Am J Respir Crit Care Med; 2017 Nov; 196(10):1353. PubMed ID: 28358994
    [No Abstract]   [Full Text] [Related]  

  • 2. Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy.
    Venerito V; Lopalco G; Anelli MG; Cacciapaglia F; Iannone F
    Rheumatology (Oxford); 2019 Mar; 58(3):440. PubMed ID: 30212893
    [No Abstract]   [Full Text] [Related]  

  • 3. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.
    Valor-Méndez L; Voskens C; Rech J; Kleyer A; Schett G
    Rheumatology (Oxford); 2021 Apr; 60(4):e122-e123. PubMed ID: 33141876
    [No Abstract]   [Full Text] [Related]  

  • 4. Baricitinib (olumiant) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):120-121. PubMed ID: 30036348
    [No Abstract]   [Full Text] [Related]  

  • 5. Resolution of exacerbated rheumatoid arthritis-associated interstitial lung disease under baricitinib treatment.
    Komai T; Sawada T; Tsuchiya H; Harada H; Shoda H; Fujio K
    Scand J Rheumatol; 2024 Mar; 53(2):146-148. PubMed ID: 38031721
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
    Nousari Y; Wu BC; Valenzuela G
    Clin Exp Dermatol; 2021 Oct; 46(7):1330-1332. PubMed ID: 33914946
    [No Abstract]   [Full Text] [Related]  

  • 7. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of baricitinib in the treatment of rheumatoid arthritis.
    Richez C; Truchetet ME; Kostine M; Schaeverbeke T; Bannwarth B
    Expert Opin Pharmacother; 2017 Sep; 18(13):1399-1407. PubMed ID: 28737053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib: JAK inhibition for rheumatoid arthritis.
    Gras J
    Drugs Today (Barc); 2016 Oct; 52(10):543-550. PubMed ID: 27910962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus Enteritis in a Patient with Rheumatoid Arthritis Receiving Baricitinib.
    Sugawara E; Matsui K; Amasaki Y
    J Rheumatol; 2020 Dec; 47(12):1835-1836. PubMed ID: 33262287
    [No Abstract]   [Full Text] [Related]  

  • 14. Baricitinib for juvenile idiopathic arthritis: a monocentric case series.
    Maccora I; Oliverio T; Pagnini I; Marrani E; Mastrolia MV; Simonini G
    Ann Rheum Dis; 2023 Jul; 82(7):994-995. PubMed ID: 36754594
    [No Abstract]   [Full Text] [Related]  

  • 15. Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?
    Bukhari M
    Rheumatology (Oxford); 2016 Sep; 55(9):1531-3. PubMed ID: 26935649
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).
    Glace B; Gottenberg JE; Mariette X; Philippe R; Pereira B; Lequerré T; Berthelot JM; Dougados M; Toussirot E; Pham T; Allanore Y; Loeuille D; Euller-Ziegler L; Soubrier M
    Ann Rheum Dis; 2012 Aug; 71(8):1429-31. PubMed ID: 22504557
    [No Abstract]   [Full Text] [Related]  

  • 17. Repigmentation of vitiligo with oral baricitinib.
    Mumford BP; Gibson A; Chong AH
    Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
    [No Abstract]   [Full Text] [Related]  

  • 18. Baricitinib: First Global Approval.
    Markham A
    Drugs; 2017 Apr; 77(6):697-704. PubMed ID: 28290136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome.
    Boleto G; Cren JB; Avouac J; Allanore Y
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):163-164. PubMed ID: 34251322
    [No Abstract]   [Full Text] [Related]  

  • 20. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
    Iwata S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.